Promising Nanotechnology Stocks To Research – April 30th

OSI Systems, NVE, Clene, Biodexa Pharmaceuticals, Virpax Pharmaceuticals, and Clene are the seven Nanotechnology stocks to watch today, according to MarketBeat’s stock screener tool. Error: Response status code does not indicate success: 429 (Too Many Requests). These companies had the highest dollar trading volume of any Nanotechnology stocks within the last several days.

OSI Systems (OSIS)

OSI Systems, Inc. designs and manufactures electronic systems and components. It operates in three segments: Security, Healthcare, and Optoelectronics and Manufacturing. The Security segment offers baggage and parcel inspection, cargo and vehicle inspection, hold baggage and people screening, radiation monitoring, explosive and narcotics trace detection systems, and optical inspection systems under the Rapiscan name.

Shares of NASDAQ OSIS traded down $0.33 during midday trading on Wednesday, reaching $202.79. The stock had a trading volume of 57,233 shares, compared to its average volume of 183,828. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.25 and a current ratio of 1.88. The firm has a market cap of $3.41 billion, a price-to-earnings ratio of 26.10, a price-to-earnings-growth ratio of 1.81 and a beta of 1.19. The company’s 50 day moving average price is $192.00 and its 200 day moving average price is $178.35. OSI Systems has a twelve month low of $129.18 and a twelve month high of $220.00.

NVE (NVEC)

NVE Corporation develops and sells devices that use spintronics, a nanotechnology that relies on electron spin to acquire, store, and transmit information in the United States and internationally. The company manufactures spintronic products, including sensors and couplers for use in acquiring and transmitting data.

Shares of NVE stock traded down $0.95 on Wednesday, reaching $57.38. 6,703 shares of the company’s stock were exchanged, compared to its average volume of 22,420. The company has a market capitalization of $277.55 million, a P/E ratio of 18.51 and a beta of 1.05. NVE has a 52 week low of $51.50 and a 52 week high of $89.98. The firm’s 50-day moving average is $62.78 and its two-hundred day moving average is $72.49.

Clene (CLNN)

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.

Shares of CLNN remained flat at $3.04 during trading hours on Wednesday. The stock had a trading volume of 27,935 shares, compared to its average volume of 77,902. The business’s fifty day moving average is $3.61 and its 200 day moving average is $4.47. The firm has a market cap of $26.13 million, a price-to-earnings ratio of -0.58 and a beta of 0.46. Clene has a 12 month low of $2.57 and a 12 month high of $9.20.

Biodexa Pharmaceuticals (BDRX)

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.

BDRX stock traded down $0.04 during midday trading on Wednesday, reaching $1.45. 9,024 shares of the company’s stock traded hands, compared to its average volume of 583,695. The firm’s fifty day moving average price is $2.00 and its 200-day moving average price is $3.84. Biodexa Pharmaceuticals has a 52 week low of $1.14 and a 52 week high of $74.00.

Virpax Pharmaceuticals (VRPX)

Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.

Shares of Virpax Pharmaceuticals stock traded up $0.01 on Wednesday, hitting $0.26. The company had a trading volume of 6,436 shares, compared to its average volume of 201,226. Virpax Pharmaceuticals has a 1 year low of $0.13 and a 1 year high of $84.75. The stock has a 50 day moving average of $2.31 and a 200-day moving average of $8.02.

Clene (CLNNW)

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.

NASDAQ:CLNNW traded down $0.00 during trading hours on Wednesday, hitting $0.03. 344 shares of the company traded hands, compared to its average volume of 12,045. Clene has a one year low of $0.02 and a one year high of $0.08. The firm’s 50-day simple moving average is $0.04 and its 200-day simple moving average is $0.04.